What is Tranquil Clinical Research?
Tranquil Clinical Research operates as a comprehensive Contract Research Organization (CRO), adept at managing all phases of clinical trials from inception to completion. The company distinguishes itself with a specialized focus on early-phase studies, including a dedicated hospital-based Phase I unit. This capability allows Tranquil to serve a diverse clientele, ranging from emerging biotech startups to established global pharmaceutical and device manufacturers. Their service portfolio is extensive, covering critical areas such as clinical trial monitoring, robust data management, expert medical monitoring, meticulous project management, and essential regulatory affairs support. With a legacy spanning over three decades, Tranquil Clinical Research has consistently prioritized innovation and quality, delivering end-to-end solutions for complex clinical trial endeavors.
How much funding has Tranquil Clinical Research raised?
Tranquil Clinical Research has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Tranquil Clinical Research
PPP
Public-Private Partnership
What's next for Tranquil Clinical Research?
The substantial backing indicated by the $150K suggests Tranquil Clinical Research is in a mature growth phase, likely leveraging this capital for scaling operations, enhancing technological infrastructure, or expanding its service offerings to meet the evolving demands of the pharmaceutical and biotech industries. The recent strategic investment, contextualized within a large-scale late-stage funding environment, points towards a strategic push for market consolidation or significant R&D acceleration. Future developments may involve strategic partnerships, geographic expansion, or the integration of advanced data analytics to further optimize clinical trial outcomes.
See full Tranquil Clinical Research company page
